


### Supplemental figure 1: Study design and treatment schema

#### Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial



CR, complete response; irRC, immune-related response criteria; PD, progressive disease; PFU, plaque-forming unit; Q2W, every 2 weeks; Q3W, every 3 weeks; T-VEC, talimogene laherparepvec.